Iga Nephropathy
📧 Sign up to get email alerts when something new happens for Iga Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Efficacy and Safety Study of HS-10542 for IgA Nephropathy [Phase 2]
Phase 2 clinical trial update for HS-10542 in IgA nephropathy, with the study currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. [Phase 2]
A Phase 2 study evaluating the efficacy and safety of HR19042 capsules for IgA nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Study of BHV-1400 in IgA Nephropathy [Phase 1]
This document announces an ongoing Phase 1 clinical trial evaluating BHV-1400 for IgA nephropathy, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment [Phase 1]
Phase 1 study of RG002C0106 injection in adults with normal renal function and mild-to-moderate renal impairment; the trial is not yet recru…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy [Phase 3]
This clinical trial update describes a rollover extension program to evaluate the long-term safety and tolerability of open-label iptacopan …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN [Phase 3]
A Phase III clinical trial to evaluate the efficacy and safety of HSK39297 tablet in adults with primary IgA nephropathy is currently recrui…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy [Phase 4]
This document discusses a Phase 4 trial evaluating extended TARPEYO treatment beyond 9 months in adults with primary IgA nephropathy. The st…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease [Phase 1]
Phase 1 clinical trial update for a CAR T-cell therapy targeting CD19 and BCMA in autoimmune conditions, with recruiting status and potentia…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy [Phase 2]
Novartis conducted a Phase 2 randomized, double-blind, placebo-controlled crossover trial of atrasentan in patients with IgA nephropathy. Th…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy [Phase 1]
Takeda-sponsored Phase 1 trial of Mezagitamab in adults with primary IgA nephropathy has completed.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Managed Access Programs for EXV811, Atrasentan
This release describes managed access programs for EXV811 (Atrasentan) in IgA nephropathy, provided by Novartis to eligible patients outside…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy [NA]
This clinical trial update notes a randomized controlled study evaluating Shenqi Yishen Granules for IgA nephropathy, with the trial not yet…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: A Study of SHR-2173 in Participants With Primary IgA Nephropathy [Phase 2]
This entry provides a Phase 2 clinical trial update for SHR-2173 in primary IgA nephropathy, with the study not yet recruiting.
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Atacicept in Multiple Glomerular Diseases [Phase 2]
Phase 2 clinical trial evaluating atacicept in multiple glomerular diseases is currently recruiting, including primary membranous nephropath…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
A multi-center, open-label prospective study evaluating early initiation of a targeted-release formulation of budesonide in patients with Ig…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy [Phase 2]
Phase IIa clinical study of RG002C0106 injection for IgA nephropathy is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects [Phase 1]
Phase 1 trial comparing capsule and tablet formulations of HRS-5965 in healthy subjects has been completed.
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of LNP023 (iptacopan) in primary IgA nephropathy has completed.
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases [Phase 2]
Travere Therapeutics is running a phase 2 pediatric trial of sparsentan for proteinuric glomerular diseases, including Focal Segmental Glome…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) [NA]
The document is a ClinicalTrials.gov entry announcing ongoing recruitment for a study to identify and characterize IgA with nephritogenic po…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 study of ARO-C3 from Arrowhead Pharmaceuticals in adults, including healthy volunteers a…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: A Study of Telitacicept for IgA Nephropathy (TELIGAN) [Phase 3]
Phase 3 trial update for telitacicept in primary IgA nephropathy; the study is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy [Phase 3]
A Phase 3 trial evaluating the safety and efficacy of OMS721 (narsoplimab) in IgA nephropathy has been terminated, with results posted.
-
EMA approval · 2025-12-08EMA Authorised: Filspari (sparsentan) — Vifor France
The European Medicines Agency has authorised Filspari (sparsentan) for glomerulonephritis, including IgA nephropathy, with orphan designatio…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease [EARLY_Phase 1]
Update on an early-phase trial of anti-CD19/BCMA CAR-NK cells for B cell–mediated autoimmune diseases, with recruitment ongoing.